Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Salix Pharmaceuticals Ltd SLXP

Healthcare Drug Manufacturers - Specialty & Generic

Recent & Breaking News (NDAQ:SLXP)

Salix Pharmaceuticals Acquires Worldwide Rights to Olon's Intellectual Property Relating to Amorphous Rifaximin

Business Wire May 30, 2013

Salix Pharmaceuticals Announces Statistically Significant Results for Budesonide Foam in the Treatment of Active Mild to Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis in Two Pivotal Phase 3 Studies

Business Wire May 22, 2013

Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2013

Business Wire May 17, 2013

Salix Pharmaceuticals Reports 1Q2013 Results

Business Wire May 9, 2013

Salix Pharmaceuticals to Present at BofA Merrill Lynch 2013 Health Care Conference

Business Wire May 7, 2013

Salix Pharmaceuticals Announces 1Q2013 Financial Results Conference Call and Webcast

Business Wire April 25, 2013

Investing in Specialty Pharmaceuticals: Focus on Merus Labs International Inc.

Accesswire April 22, 2013

Salix Pharmaceuticals Commits $1.125M to AGA Research Foundation

PR Newswire March 13, 2013

A Forward Look, The Year Ahead - Research Report on The Walt Disney Company, Time Warner Inc., Hyperion Therapeutics Inc., Salix Pharmaceuticals, Ltd. and Lions Gate Entertainment Corp.

PR Newswire March 13, 2013

Salix Pharmaceuticals Reports 4Q2012 and FY2012 Results

Business Wire February 28, 2013

Salix Pharmaceuticals to Present at Two Investment Conferences in March

Business Wire February 25, 2013

Salix Pharmaceuticals Announces 4Q2012 and FY2012 Financial Results Conference Call and Webcast

Business Wire February 14, 2013

FDA Approves Fulyzaq(tm) (Crofelemer) 125 mg Delayed-Release Tablets for the Symptomatic Relief of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy (ART)

Business Wire January 2, 2013

Salix Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Business Wire January 2, 2013

Should Recent Insider Selling on LSI, UNM, NXTM and SLXP Matter to You?

Marketwired December 26, 2012